Kartos Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Kartos Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 3 currently recruiting 3 completed early-phase tilt upper quartile by trial count

Kartos Therapeutics: 8 sponsored US clinical trials, 3 recruiting.

Kartos Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignancy, with 1 trials.

Upper-quartile sponsor footprint

Kartos Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 3

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135
RECRUITING Phase 2

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

NCT05797831
RECRUITING Phase 1

KRT-232 and TKI Study in Chronic Myeloid Leukemia

NCT04835584
TERMINATED Phase 2

KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT05027867
TERMINATED Phase 1

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

NCT04113616
COMPLETED Phase 1

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

NCT02110355
COMPLETED Phase 1

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

NCT02016729
COMPLETED Phase 1

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

NCT01723020

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2
Phase 3 1

Therapeutic Areas

Advanced Malignancy 1
Oncology Patients 1
MF 1
Post-ET Myelofibrosis 1
Post-PV MF 1
Chronic Myeloid Leukemia 1
Myelofibrosis 1
Oncology 1
Primary Myelofibrosis 1
Acute Myeloid Leukemia 1

What is open in the Kartos Therapeutics pipeline

3 recruiting of 8 indexed (38% open); 3 completed (38%).

Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Advanced Malignancy (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Kartos Therapeutics: open-pipeline peers nationwide

Peers matched on 8 registered trials and 38% open enrollment, not the therapeutic-area sidebar.

Kartos Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 8.088.1 0%10%20%30%40% Total trials Recruiting share Kartos TherapeuticsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)American Thrombosis and Hemostasis NetworkAskBioAthletic Greens InternationalBanner Health
Kartos Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Kartos Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 38% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Kartos Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of Kartos Therapeutics or any single study.

  • 3 of Kartos Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Advanced Malignancy is the condition Kartos Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Malignancy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Kartos Therapeutics pipeline card: 8 registered trials from official public datasets.Report a data error.